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Patients who have experienced a first cerebral ischemic event are at increased risk of
recurrent stroke. There is strong evidence that low-level inflammation as measured by
high sensitivity C-reactive protein (hs-CRP) is a predictor of further ischemic events. Other
mechanisms implicated in the pathogenesis of stroke may play a role in determining
the risk of secondary events, including oxidative stress and the adaptive response to it
and activation of neuroprotective pathways by hypoxia, for instance through induction
of erythropoietin (EPO). This study investigated the association of the levels of CRP,
peroxiredoxin 1 (PRDX1, an indicator of the physiological response to oxidative stress)
and EPO (a neuroprotective factor produced in response to hypoxia) with the risk of
a second ischemic event. Eighty patients with a diagnosis of lacunar stroke or transient
ischemic attack (TIA) were included in the study and a blood sample was collected within
14 days from the initial event. Hs-CRP, PRDX1, and EPO were measured by ELISA.
Further ischemic events were recorded with a mean follow-up of 42 months (min 24,
max 64). Multivariate analysis showed that only CRP was an independent predictor of
further events with an observed risk (OR) of 1.14 (P = 0.034, 95% CI 1.01–1.29). No
association was observed with the levels of PRDX1 or EPO. A receiver operating curve
(ROC) determined a cut-off CRP level of 3.25µg/ml, with a 46% sensitivity and 81%
specificity. Low-level inflammation as detected by hs-CRP is an independent predictor
of recurrent cerebrovascular ischemic events.
Keywords: TIA, lacunar stroke, cerebral ischemia, inflammation, oxidative stress, CRP, peroxiredoxin 1,
erythropoietin
INTRODUCTION
Stroke is a leading cause of death and long-term disability worldwide (1, 2). Of the total number of
prevalent strokes, more than 80% are ischemic (1). Patients who have experienced a cardiovascular
event are at higher risk for further events, with a cumulative recurrence rate of ∼5% at 1 year
(3, 4). Established risk factors include smoking, hypertension (HTN), high body mass index (BMI),
atrial fibrillation, diabetes mellitus, atherosclerosis (1, 5). Finding predictive markers for recurrent
cardiovascular events could be vital in identifying potential preventive measures.
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There is evidence to suggest that stroke is associated with
inflammation (6). High sensitivity C-reactive protein (hs-CRP)
detects low level inflammation and correlates with cardiovascular
risk in the general population (7–10). In a recent meta-
analysis, high levels of CRP were associated with ischemic
but not haemorrhagic stroke (9). CRP and other inflammatory
biomarkers, such as IL-6 and IL-8, are increased after stroke and
have been linked to recurrent vascular events (11–16). However,
in one study IL-6 (but not CRP) was associated with higher risk
of cerebrovascular events (17) and in patients with large-artery
atherosclerotic stroke CRP was associated with poor functional
disability but not with recurrent vascular events (18).
Oxidative stress has also been implicated in stroke (19).
Peroxiredoxins (PRDXs) are intracellular antioxidant enzymes
that can be secreted, and their circulating levels are increased
under oxidative stress (20). Circulating levels of PRDX1 are
elevated in patients following acute stroke (21) and a recent
study highlighted PRDX1 as a biomarker of stroke onset
early after stroke (22). Secreted PRDXs may then contribute
to the inflammatory pathway by activating the production of
inflammatory cytokines (23).
Erythropoietin (EPO) is an hypoxia-induced cytokine and
has neuroprotective activities in various models of brain injury,
including hypoxia and stroke (24, 25). In a clinical trial, EPO
administration after ischemic stroke improved clinical recovery
and brain damage in patients not receiving thrombolysis (26, 27).
In another study, EPO administration did not affect recurrent
stroke or mortality but improved long-term neurological
outcome (28). A recent meta-analysis confirmed the protective
role of exogenously administered EPO in stroke (29). However,
the significance of circulating EPO levels as a cardiovascular risk
biomarker is not understood. A study reported that an increase
in serum EPO levels after ischemic stroke was associated with a
favorable outcome (30). However, high serum EPO levels are also
associated with impaired prognosis in patients with chronic heart
failure (31).
In this study, we investigated the possible significance of
biomarkers related to variousmechanisms that could increase the
risk of a second stroke after recovery from one. We looked in
particular at the role of hs-CRP as a biomarker of inflammation,
PRDX1 as a marker of oxidative stress and EPO as a potential
neuroprotective mediator in predicting further ischemic events




The Arterial Stiffness In lacunar Stroke and TIA study
(ASIST) was an observational prospective cohort study
undertaken at the Brighton and Sussex University NHS
Trust. The study was approved by the UK National Research
Ethics Service (NRES; 14/LO/0189) and was conducted in
accordance with Good Clinical Practice Guidelines and
with the Declaration of Helsinki. All patients gave written
informed consent.
Clinical Measurements
Patients for the ASIST study each attended a laboratory visit
within 14 days of their diagnosed TIA or lacunar stroke. Baseline
clinical and demographic information was collected and clinical
measures such as blood pressure (BP), BMI etc. were performed
as previously described (32). Arterial stiffness was calculated
using cfPWV (carotid-femoral pulse wave velocity) measured
with Complior R©Artech, France, and with the CAVI R© Fukuda,
Japan (cardio-ankle vascular index) method. Blood samples were
taken for measurement of various biomarkers by ELISA assays.
Blood was collected in EDTA-containing tubes and plasma was
frozen at−80◦C until use.
Participants
Ninety-six patients with a diagnosis of lacunar stroke or TIA
confirmed by a stroke physician were recruited to the ASIST
study. Of these, 80 patients with plasma samples were evaluated
in this study. The follow-up period ranged from 24 to 64
months (mean 42 months). The patients received standard
National Institute for Health and Clinical Excellence (NICE)
guidance therapy for stroke or TIA depending on type of event
and comorbidities.
ELISAs
High sensitivity C-reactive protein (hs-CRP), erythropoietin
(EPO), and peroxiredoxin 1 (PRDX1) were measured in plasma
samples with commercially available ELISA kits (hs-CRP: DRG
TABLE 1 | Descriptive analysis of patients and univariate analyses of variables
associated with further ischemic events.
Further events P-value
Total, n = 78 (–), n = 54 (+), n = 24
Previous stroke 26.9 (21) 25.9 (14) 29.2 (7) 0.397
Previous TIA 73.1 (57) 74.1 (40) 70.8 (17) 0.648
Age (years) 70.2 ± 11.2 69.5 ± 10.6 71.8 ± 12.7 0.412
Male sex 67.9 (53) 70.4 (38) 62.5 (15) 0.493
Smoking status 65.4 (51) 66.7 (36) 62.5 (15) 0.721
Diabetes 24.4 (19) 16.7 (9) 41.7 (10) 0.021*
BMI (Kg/m2) 27.24 ± 4.8 27.1 ± 4.7 27.4 ± 5.2 0.746
Atrial fibrillation 17.9 (14) 20.4 (11) 12.5 (3) 0.408
Diagnosis of
HTN
47.4 (37) 42.6 (23) 58.3 (14) 0.202
Average systolic
BP
143.0 ± 18.5 142.3 ± 19.0 144.4 ± 17.7 0.650
Average diastolic
BP
79.3 [73.3–88.0] 80.0 [75.1–88.1] 77.3 [71.5–87.6] 0.241
Hs-CRP (µg/ml) 1.9 [0.8–3.4] 1.6 [0.7–3.0] 2.8 [1.2–9.9] 0.019*
EPO (mIU/ml) 8.7 [6.3–12.0] 9.1 [6.4–12.6] 8.2 [5.8–11.7] 0.362
PRDX1 (µg/ml) 6.3 ± 1.0$ 6.2 ± 1.0∧ 6.5 ± 0.8§ 0.627
Values are given asmean±SD ormedian [interquartile range] for continuous data normally
or not normally distributed, respectively, and as percentages (n) for categorical data. TIA,
transient ischemic attack; BMI, body mass index; HTN, hypertension; BP, blood pressure;
hs-CRP, high sensitivity C-reactive protein; EPO, erythropoietin; PRDX1, peroxiredoxin 1.
P-value from univariate logistic regression. Values with statistical significance are in bold
(*P < 0.05). $n = 40; ∧n = 31; §n = 9.
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FIGURE 1 | CRP, EPO, and PRDX1 levels in patients. Since the plasma levels
of hs-CRP and EPO are not normally distributed, the data in (A,B) are
presented as box and whiskers plot (minimum, 1st quartile, median, 3rd
quartile, maximum); n = 54 for the group with no further events and n = 24 for
the group with further events. The plasma levels of PRDX1 are normally
distributed and therefore the data in (C) are presented as mean ± SD; n = 31
(Continued)
FIGURE 1 | for no further events and n = 9 for further events. In all panels,
each dot indicates individual data from each subject. *P < 0.05 by
Mann-Whitney U-test. No significant difference between the two groups of
data was detected in (B,C) by Mann-Whitney U-test and Student’s t-test,
respectively.
Instruments GmbH, Oxford Biosystems; EPO: R&D Systems,
Bio-Techne; PRDX1: Antibodies-online, Caltag Medsystems).
PRDX1 was measured only in 40 patients samples selected
at random.
Statistical Analysis
The normality distribution of the data was determined with
GraphPad Prism v8.3.0, using the D’Agostino & Pearson test.
Normally distributed data were presented as mean ± SD and
not normally distributed data as median [interquartile range].
The statistical significance between the groups with and without
further cerebrovascular events was assessed with the Mann-
Whitney U-test for data not normally distributed and with the
Student’s t-test for data normally distributed, both in GraphPad
Prism. Prism was also used to create a receiver operating
characteristic (ROC) curve, in order to establish a cut-off
point for hs-CRP that optimally predicted the occurrence of
further events.
Pearson correlation analysis and univariate and multivariate
binary logistic regression analyses were carried out using
SPSS v25. Odd ratios (ORs) and 95% confidence intervals
(95% CI) were determined. Analysis was adjusted for previous
stroke, previous TIA, age, sex, smoking status, diabetes, BMI,
atrial fibrillation, diagnosis of HTN, average systolic BP, and
average diastolic BP. For all analyses, P < 0.05 was considered
statistically significant.
RESULTS
This study aimed to investigate whether plasma biomarkers
could predict further ischemic events in patients diagnosed
with a TIA or lacunar stroke. PRDX1 was measured in
40 patients and hs-CRP and EPO were measured in 80
patients. Of these, two were excluded because they presented
hs-CRP >50µg/ml associated with white blood cell (WBC)
count >10,000/ml, a marker of acute bacterial infections (33),
leaving 78 patients. In the mean follow-up of 42 months, 24
further cerebrovascular events occurred. Among the 40 patients
where PRDX1 was measured, nine further cerebrovascular
events occurred.
Table 1 displays the baseline patient characteristics and the
univariate analysis of variables associated with further ischemic
cerebrovascular events during follow-up. Among the plasma
biomarkers measured, only hs-CRP was associated with an
increased risk of recurrent TIA/stroke (P < 0.05).
Figure 1 shows the levels of the three biomarkers in patients
with and without further events. CRP levels (Figure 1A) were
significantly higher in the group of patients who experienced a
further ischemic event (P = 0.041 by Mann-Whitney U-test).
CRP median levels and interquartile range in the two groups are
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TABLE 2 | CRP is an independent predictor of further cerebrovascular events.
B SE P-value OR 95% CI for OR
Lower Upper
Previous stroke 0.214 0.707 0.762 1.238 0.310 4.953
Previous TIA 0.255 0.683 0.709 1.290 0.339 4.917
Age −0.019 0.039 0.618 0.981 0.909 1.059
Sex −0.669 0.685 0.329 0.512 0.134 1.963
Smoking status 0.094 0.635 0.882 1.099 0.317 3.813
Diabetes 1.025 0.689 0.137 2.786 0.723 10.742
BMI −0.024 0.071 0.734 0.976 0.850 1.121
Atrial fibrillation −0.783 0.912 0.390 0.457 0.076 2.729
Diagnosis of HTN 0.621 0.612 0.310 1.861 0.561 6.178
Average systolic BP 0.030 0.025 0.245 1.030 0.980 1.083
Average diastolic BP −0.048 0.047 0.311 0.953 0.869 1.046
Hs-CRP (µg/ml) 0.131 0.062 0.034* 1.140 1.010 1.286
Multivariate binary logistic regression analysis. All patients (n = 78) were included in the analysis. B, estimated regression coefficient; SE, standard error; OR, odds ratio. Other
abbreviations as in the legend to Table 1. Values reaching statistical significance are in bold (*P < 0.05).
FIGURE 2 | ROC curve for predicting further cerebrovascular events through
measure of plasma hs-CRP levels. The arrow shows the cut-off point of
hs-CRP = 3.25µg/ml corresponding to 46% sensitivity and 81% specificity.
shown in the figure and also reported in Table 1. There were no
significant differences in the levels of EPO (Figure 1B) or PRDX1
(Figure 1C).
We therefore analyzed further the significance of CRP
as a predictor of further events. In a multivariate binary
logistic regression analysis, after correcting for previous stroke,
previous TIA, age, sex, smoking status, diabetes, BMI, atrial
fibrillation, diagnosis of HTN, average systolic BP, and average
diastolic BP, only CRP was an independent predictor of further
cerebrovascular events, with OR 1.14 (P = 0.034, 95% CI 1.01–
1.29; Table 2). The Pearson correlation between CRP and further
events was 0.34 (P = 0.002).
We then plotted the levels of CRP as a ROC curve to determine
the optimal cut-off value. As shown in Figure 2, a cut-off point of
CRP level of 3.25µg/ml was determined, with a 46% sensitivity
and 81% specificity. To further explore the role of CRP in
predicting further ischemic events, its levels were assessed as
a binary variable using the cut-off value obtained from the
ROC curve, and this categorized variable was included in the
multivariate analysis (Table 3). This increased the OR from 1.14,
obtained using CRP as a continuous variable (Table 2), to 8.32 (P
= 0.005, 95% CI 1.93–35.91; Table 3).
DISCUSSION
This study shows that CRP levels after a minor first
cerebrovascular event (TIA or lacunar stroke) can contribute
to identifying patients at high risk of a second ischemic event.
Elevated levels of CRP (3–6µg/ml) are a known predictor of
ischemic stroke and TIA, as shown in a large study based on the
Framingham cohort (7). Subsequent studies have investigated
whether CRP levels after an initial ischemic event predict the
risk of a second event, in patients with diverse stroke etiologies,
measuring CRP at different times after stroke and with different
follow-up times.
In general, in patients with major strokes, CRP levels correlate
with stroke severity and can be a marker of stroke etiology,
with higher CRP in more severe cardioembolic or large artery
disease stroke than in stroke caused by small artery disease
(13, 34–36). CRP levels increase in the first 48 h after onset,
are still elevated at 7 days and remain high for 3–6 months
after stroke (11, 34). CRP levels measured after stroke correlated
with recurrence both in studies limited to cardioembolic stroke
(16) or to large-artery occlusive disease (12) and also in studies
where patients with ischemic stroke of different etiologies were
included (11, 13). Interestingly, CRP was measured at different
times after stroke in different studies, either in the early hours
after stroke (11, 13) or between 7 days and 3–6months from onset
(12, 16).
This study was focused on minor stroke, either TIA or lacunar
stroke. Since CRP levels are associated with severity and size of
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TABLE 3 | Levels of hs-CRP >3.25µg/ml optimally predict further ischemic events.
B SE P-value OR 95% CI for OR
Lower Upper
Previous stroke −0.038 0.743 0.959 0.962 0.224 4.132
Previous TIA 0.322 0.710 0.650 1.380 0.343 5.550
Age −0.046 0.041 0.264 0.955 0.881 1.035
Sex −0.832 0.709 0.241 0.435 0.109 1.746
Smoking status 0.279 0.651 0.668 1.322 0.369 4.734
Diabetes 1.335 0.678 0.049* 3.800 1.005 14.361
BMI −0.039 0.073 0.593 0.962 0.834 1.110
Atrial fibrillation −0.852 0.887 0.337 0.427 0.075 2.427
Diagnosis of HTN 0.758 0.626 0.226 2.133 0.626 7.275
Average systolic BP 0.035 0.026 0.183 1.035 0.984 1.089
Average diastolic BP −0.082 0.051 0.103 0.921 0.834 1.017
Hs-CRP >3.25µg/ml 2.119 0.746 0.005* 8.321 1.928 35.907
Multivariate binary logistic regression analysis including hs-CRP as a categorized binary variable using the cut-off value of 3.25µg/ml. All patients (n = 78) were included in the analysis.
Patients were divided into two groups and hs-CRP was given value 0 in patients with CRP <3.25µg/ml (n = 57) and value 1 in patients with CRP >3.25µg/ml (n = 21). B, estimated
regression coefficient; SE, standard error; OR, odds ratio. Other abbreviations as in the legend to Table 1. Values with statistical significance are in bold (*P < 0.05).
the lesion (36), in minor stroke CRP levels are less likely to reflect
stroke severity butmight be amarker of underlying inflammation
and therefore are less subject to variation depending on time from
onset. In previous studies in patients with TIA (14) or lacunar
stroke (37) CRP levels measured within 24 h or <3 weeks after
stroke, respectively, were an independent predictor of further
events. Our study, where both patients with TIA or lacunar stroke
were included and CRP was measured within 14 days from stroke
or TIA onset, confirms the results obtained by Purroy et al. in
TIA patients and by Elkind et al. in patients with lacunar stroke
(14, 37). Using a ROC curve our study identified a cut-off of
CRP of 3.25µg/ml, measured within 14 days from onset, as an
independent predictor of further events. Purroy et al. (14) also
used a ROC curve to identify a cut-off of 4.1µg/ml and Elkind
et al. (37) found that higher risk was associated with levels of
CRP> 4.85µg/ml (top quartile). Our results show that even
lower levels of CRP (>3.25µg/ml), measured within 14 days
from onset, can help identify patients at risk of second ischemic
events after experiencing a minor stroke and support the finding
that even low levels of inflammation should be considered a
vascular risk factor both in primary prevention and for stroke
recurrence (8–10, 37, 38).
Interestingly, in a study focused on TIA patients, Cucchiara
et al. found no association between levels of CRP> 3µg/ml
measured within 48 h from onset and risk of second events
(39). However, the follow-up in that study was 3 months. In
our study the patients were followed up for a longer period
of time (mean 42 months, min 24, max 64 months), that was
longer than the 1 year follow-up reported by most studies
(11–14, 16).
In our study monovariate analysis showed that diabetes is
also a predictor of the risk of a further event, in agreement
with studies showing that diabetes is associated with recurrent
stroke after a first ischemic event (40–42). Higher CRP
levels are also known to be associated with the risk of
diabetes (43, 44). However, in our study, multivariate analysis
showed that CRP is an independent predictor (Table 2), again
supporting the view that low-level inflammation is associated
with cardiovascular risk.
Our study also explored EPO and PRDX1 levels as potential
indicators of the role of hypoxia response and oxidative stress
in the occurrence of further events. EPO is typically induced
by hypoxia. Activation of hypoxia-inducible factor (HIF)-1α by
hypoxia is an adaptive response that leads to the induction of
several mediators that can afford protection against hypoxia,
including EPO (24). The study by Aberg et al. reported a small
increase in circulating EPO in stroke patients compared to
healthy controls (mean 9.3 vs. 7.7 mIU/mL, respectively) (30).
In that study, higher EPO levels were associated with a more
favorable outcome, which would agree with the many preclinical
studies on a protective effect of EPO in stroke (25, 45). On
the other hand, data from the PREVEND study in patients
with heart failure showed that higher EPO levels are associated
with an increased risk of stroke in women (46). Our study did
not show any association between EPO levels and the risk of
further events.
Another transcription factor whose activation may be
protective in cerebral ischemia is nuclear factor erythroid 2-
related factor 2 (NRF2). NRF2 target genes include several
antioxidant enzymes including PRDX1, thioredoxin 1 (TXN1),
and heme oxygenase 1 (HMOX1) and its activation affords
protection in animal models of stroke (47, 48). Although a
previous study reported that the circulating levels of the NRF2
target gene PRDX1 are almost doubled in stroke patients (21), we
could not find any significant association in its levels and the risk
of further events.
There are some limitations in this study. This is a relatively
small study since only 78 patients were included. Blood was
taken at the first laboratory visit and therefore within 14
days from onset which was not at the same time from
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onset for all patients. In addition, PRDX1 was measured
in only 40 patients of which nine experienced a further
event. The very high variability of PRDX1 levels in patients
with no further events, observed after measuring PRDX1 in
approximately half of the patients, strongly suggested that
PRDX1 was not a good discriminator between the two groups
and therefore no further measurements were undertaken;
however, we cannot exclude the possibility that significant
results could be obtained in a significantly larger study. It
is also important to highlight that in our study we did not
have a control population; only patients who had an ischemic
event were included. Nevertheless, these findings suggest that
inflammation, rather than neuroprotective or antioxidant factors
(at least EPO and PRDX1), is a possible determinant of the
occurrence of secondary ischemic events in patients with TIA or
lacunar stroke.
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